A Phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the efficacy and safety of 40 mg/day KW-6002 as monotherapy in subjects w/PD
|Effective start/end date||6/15/05 → 12/15/06|
- SYNEOS HEALTH, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.